The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma
Malignant mesotheliomas frequently harbor loss of CDK2NA which is associated with shorter survival and may represent a novel treatment strategy for these patients. Dean A. Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, presents findings of a Phase II study investigating the efficacy of abemaciclib, a CDK4/6 inhibitor in patients with p16ink4a negative relapsed mesothelioma in the MiST2 study (NCT03654833). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
